Recursion announces the close of a $121 million Series C financing to advance its machine learning-enabled approach to drug discovery and development.

Recursion said it will end development for four of its 11 pipeline programs—one of which the company will consider outlicensing to a partner instead—and pause a fifth program, in a pruning ...

Recursion Pharma RXRX shares have plunged 37.1% in the past month compared with the industry’s 1.4% decline. The company has also underperformed in the sector and the S&P 500 during the same ...

In the latest trading session, Recursion Pharmaceuticals (RXRX) closed at $7.66, marking a +0.13% move from the previous day. The stock outpaced the S&P 500's daily gain of 0.03%. Elsewhere, the ...

Recursion Pharmaceuticals had a busy start to the week, scrapping a rare disease asset from its pipeline as part of a strategic rethink while pulling in a $150 million private placement.

By Adriano Marchese Shares of Recursion Pharmaceuticals rose Tuesday morning after the company said slashing its workforce by 20% will extend its cash runway to the end of 2027.

Chris Gibson, Cofounder and CEO of Recursion, lays out how his company is building the biological data, and layering on AI, to assist in the development of new, effective therapeutics.

Recursion has more expressive power than iterative looping constructs. I say this because a while loop is equivalent to a tail recursive function and recursive functions need not be tail recursive.